SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-262507
Filing Date
2020-10-02
Accepted
2020-10-02 16:16:31
Documents
12
Period of Report
2020-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d85081d8k.htm   iXBRL 8-K 28680
  Complete submission text file 0001193125-20-262507.txt   152157

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alny-20200930.xsd EX-101.SCH 3067
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20200930_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20200930_pre.xml EX-101.PRE 11406
5 EXTRACTED XBRL INSTANCE DOCUMENT d85081d8k_htm.xml XML 3387
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 201220204
SIC: 2834 Pharmaceutical Preparations